Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

Food and Drug Administration officials have opened a safety review of two injectable drugs used to protect babies and ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...

FDA officials are newly scrutinizing several approved therapies to treat RSV in babies despite the fact that these shots were shown to be safe in clinical trials ...

The FDA reportedly told drugmakers that approved monoclonal antibodies to protect infants against respiratory syncytial virus ...

Among adults older adults, a respiratory syncytial virus (RSV) infection increases the risk of cardiovascular events over the ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...

Early-life viral infection programs immune cells to hijack allergy-associated maternal antibodies, driving allergy risk later ...

Respiratory syncytial virus, commonly known as RSV, is often associated with cold-like symptoms in young children.